Mizuho Lowers Nkarta (NASDAQ:NKTX) Price Target to $16.00

Nkarta (NASDAQ:NKTX - Free Report) had its price target decreased by Mizuho from $20.00 to $16.00 in a research report report published on Thursday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

A number of other research firms also recently issued reports on NKTX. Rodman & Renshaw assumed coverage on shares of Nkarta in a research report on Wednesday, October 9th. They set a "buy" rating and a $14.00 target price for the company. RODMAN&RENSHAW raised shares of Nkarta to a "strong-buy" rating in a research note on Wednesday, October 9th. Needham & Company LLC lowered their price target on Nkarta from $13.00 to $11.00 and set a "buy" rating on the stock in a research report on Friday, November 8th. HC Wainwright cut their price objective on Nkarta from $22.00 to $18.00 and set a "buy" rating for the company in a research report on Monday, November 11th. Finally, Raymond James raised shares of Nkarta from an "outperform" rating to a "strong-buy" rating and set a $16.00 price target on the stock in a research note on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $15.00.

Nkarta Stock Down 2.4 %

Shares of NASDAQ:NKTX traded down $0.06 during trading on Thursday, hitting $2.44. The stock had a trading volume of 675,723 shares, compared to its average volume of 1,145,571. Nkarta has a 12-month low of $2.38 and a 12-month high of $16.24. The stock has a market capitalization of $172.19 million, a price-to-earnings ratio of -1.33 and a beta of 0.86. The stock has a 50-day simple moving average of $3.92 and a two-hundred day simple moving average of $5.30.

Institutional Trading of Nkarta

Several hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. boosted its position in shares of Nkarta by 38.4% during the first quarter. RA Capital Management L.P. now owns 10,805,129 shares of the company's stock worth $116,803,000 after buying an additional 3,000,000 shares during the period. Vanguard Group Inc. boosted its holdings in Nkarta by 26.0% during the 1st quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company's stock valued at $21,255,000 after acquiring an additional 405,753 shares during the period. Wasatch Advisors LP grew its position in Nkarta by 31.7% in the 3rd quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company's stock valued at $8,293,000 after acquiring an additional 442,125 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Nkarta by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company's stock worth $5,294,000 after buying an additional 33,927 shares in the last quarter. Finally, State Street Corp boosted its holdings in Nkarta by 1.4% in the third quarter. State Street Corp now owns 1,098,062 shares of the company's stock valued at $4,963,000 after purchasing an additional 15,569 shares during the period. Hedge funds and other institutional investors own 80.54% of the company's stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.